cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.29245325
title: Supplementary Material for: Using Virtual Therapy for Lymphedema and Disability Post-Mastectomy: Meta-Analysis with Systematic Review

description: Introduction: This review and meta-analysis aimed to examine the effects of virtual reality (VR) therapy on lymphedema and disability management in post-mastectomy breast cancer patients, following PRISMA protocol. 
Methods: Databases were extensively searched, including Wiley Online Library, ProQuest, MEDLINE, CINAHL, Google Scholar, Science Direct, and SAGE Journals, covering studies from January 2016 to August 2024. This review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Results: Nine studies met the inclusion criteria. The findings indicate VR therapy effectively reduces post-mastectomy lymphedema and aids upper limb disability rehabilitation, with sessions lasting 10 to 50 minutes. The meta-analysis statistics showed a significant decrease in disability, measured by the DASH scale, with an effect size of -0.931 (Z score = -2.713, p = .007) and a 95% confidence interval of -1.604 to -0.259. 
Conclusions: These results strongly support VR’s efficacy in managing lymphedema and disability, recommending its integration into routine care at oncology centers and hospitals. This article explains compelling evidence that VR is effective in helping patients with lymphedema manage their disabilities. Rehabilitation programs using VR after mastectomy should be incorporated into the daily care in oncology centers and hospitals. Further interventional studies are needed to strengthen evidence and refine VR’s clinical application.
DOI: 10.6084/m9.figshare.29245325.v1
title: Supplementary Material for: Using Virtual Therapy for Lymphedema and Disability Post-Mastectomy: Meta-Analysis with Systematic Review

description: Introduction: This review and meta-analysis aimed to examine the effects of virtual reality (VR) therapy on lymphedema and disability management in post-mastectomy breast cancer patients, following PRISMA protocol. 
Methods: Databases were extensively searched, including Wiley Online Library, ProQuest, MEDLINE, CINAHL, Google Scholar, Science Direct, and SAGE Journals, covering studies from January 2016 to August 2024. This review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Results: Nine studies met the inclusion criteria. The findings indicate VR therapy effectively reduces post-mastectomy lymphedema and aids upper limb disability rehabilitation, with sessions lasting 10 to 50 minutes. The meta-analysis statistics showed a significant decrease in disability, measured by the DASH scale, with an effect size of -0.931 (Z score = -2.713, p = .007) and a 95% confidence interval of -1.604 to -0.259. 
Conclusions: These results strongly support VR’s efficacy in managing lymphedema and disability, recommending its integration into routine care at oncology centers and hospitals. This article explains compelling evidence that VR is effective in helping patients with lymphedema manage their disabilities. Rehabilitation programs using VR after mastectomy should be incorporated into the daily care in oncology centers and hospitals. Further interventional studies are needed to strengthen evidence and refine VR’s clinical application.
DOI: 10.6084/m9.figshare.29245328
title: Supplementary Material for: Clinical Outcomes in the Nephrotic Syndrome Study Network (NEPTUNE): Disease Burden and Treatment Patterns Over Time

description: Background: Among patients with proteinuric glomerular diseases, there is a paucity of high-quality evidence and substantial variation in practice patterns among nephrologists. Our objective was to describe the clinical presentation, treatment patterns, and outcomes of patients with biopsy-proven glomerular diseases in a contemporary, well-phenotyped, diverse cohort.
Methods: The Nephrotic Syndrome Study Network (NEPTUNE) is a prospective observational cohort study of children and adults with proteinuric glomerular diseases enrolled at 23 centers in the US and Canada since 2009. We included participants who underwent their first clinically indicated kidney biopsy demonstrating minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), or membranous nephropathy (MN). We described demographic and clinical characteristics at the time of biopsy and baseline visits. We analyzed treatment patterns for participants with and without immunosuppressive therapy (IST) use prior to biopsy. We described clinical outcomes including complete remission (CR) and proteinuria, stratified by IST use, at biopsy and up to 36 months’ follow-up.
Results: Among 507 NEPTUNE participants who underwent biopsy, 203 were classified as having FSGS, 193 as having MCD, and 111 as having MN. Corticosteroid exposure was high overall and highest among MCD patients. Substantial heterogeneity in treatment choices was evident, particularly among those initiating second-line therapy. The rate of kidney failure was highest, and CR rates were lowest, among patients with FSGS, who experienced ~50% cumulative probability of first remission at 36 months after biopsy. At 36 months, 49.5% of all patients were not in CR; 19.3% were not in CR despite being on IST. Additionally, 20.2% of patients had proteinuria &gt;1.5 g/g; among those on IST at their 36-month visit, 26.3% had UPCR &gt;1.5 g/g.
Conclusion: A substantial proportion of patients were not in remission and had persistent proteinuria despite being on IST three years after their first biopsy.
DOI: 10.6084/m9.figshare.29245328.v1
title: Supplementary Material for: Clinical Outcomes in the Nephrotic Syndrome Study Network (NEPTUNE): Disease Burden and Treatment Patterns Over Time

description: Background: Among patients with proteinuric glomerular diseases, there is a paucity of high-quality evidence and substantial variation in practice patterns among nephrologists. Our objective was to describe the clinical presentation, treatment patterns, and outcomes of patients with biopsy-proven glomerular diseases in a contemporary, well-phenotyped, diverse cohort.
Methods: The Nephrotic Syndrome Study Network (NEPTUNE) is a prospective observational cohort study of children and adults with proteinuric glomerular diseases enrolled at 23 centers in the US and Canada since 2009. We included participants who underwent their first clinically indicated kidney biopsy demonstrating minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), or membranous nephropathy (MN). We described demographic and clinical characteristics at the time of biopsy and baseline visits. We analyzed treatment patterns for participants with and without immunosuppressive therapy (IST) use prior to biopsy. We described clinical outcomes including complete remission (CR) and proteinuria, stratified by IST use, at biopsy and up to 36 months’ follow-up.
Results: Among 507 NEPTUNE participants who underwent biopsy, 203 were classified as having FSGS, 193 as having MCD, and 111 as having MN. Corticosteroid exposure was high overall and highest among MCD patients. Substantial heterogeneity in treatment choices was evident, particularly among those initiating second-line therapy. The rate of kidney failure was highest, and CR rates were lowest, among patients with FSGS, who experienced ~50% cumulative probability of first remission at 36 months after biopsy. At 36 months, 49.5% of all patients were not in CR; 19.3% were not in CR despite being on IST. Additionally, 20.2% of patients had proteinuria &gt;1.5 g/g; among those on IST at their 36-month visit, 26.3% had UPCR &gt;1.5 g/g.
Conclusion: A substantial proportion of patients were not in remission and had persistent proteinuria despite being on IST three years after their first biopsy.
DOI: 10.6084/m9.figshare.29245331
title: Supplementary Material for: Infection of Enterocytozoon bieneusi in a patient with long-term immunosuppression after liver transplantation: a case report and literature review

description: Enterocytozoon bieneusi (E.b) can cause opportunistic infections in immunocompromised patients especially HIV/AIDS recipients, but currently there are still few case reports of E.b infections in solid organ transplant recipients. As E.b cannot be diagnosed by routine examination and culture, it is often overlooked as a possible cause of chronic diarrhea in transplant recipients. With no known established guidelines for E.b, the effective and available treatment options are limited. In this article, we reported a case of persistent chronic diarrhea and renal failure due to E.b infection after liver transplantation, which was definitively diagnosed using metagenomic Next Generation Sequencing (mNGS). Short course of Albendazole was applied to the patient, resulting in rapid resolution of clinical symptoms and recovery of renal function. The case demonstrates the advantages of mNGS for the diagnosis of rare pathogenic bacterial infections, and together with the previous case reports further suggests Albendazole may serve as a effective therapy for the treatment of E.b for some patient.This article reviews relevant literature and provides an updated and more comprehensive reference for the selection of E.b treatment drugs. To be note, the overview showed there may be individualized differences in the efficacy of Albendazole, which needs more study.
DOI: 10.6084/m9.figshare.29245331.v1
title: Supplementary Material for: Infection of Enterocytozoon bieneusi in a patient with long-term immunosuppression after liver transplantation: a case report and literature review

description: Enterocytozoon bieneusi (E.b) can cause opportunistic infections in immunocompromised patients especially HIV/AIDS recipients, but currently there are still few case reports of E.b infections in solid organ transplant recipients. As E.b cannot be diagnosed by routine examination and culture, it is often overlooked as a possible cause of chronic diarrhea in transplant recipients. With no known established guidelines for E.b, the effective and available treatment options are limited. In this article, we reported a case of persistent chronic diarrhea and renal failure due to E.b infection after liver transplantation, which was definitively diagnosed using metagenomic Next Generation Sequencing (mNGS). Short course of Albendazole was applied to the patient, resulting in rapid resolution of clinical symptoms and recovery of renal function. The case demonstrates the advantages of mNGS for the diagnosis of rare pathogenic bacterial infections, and together with the previous case reports further suggests Albendazole may serve as a effective therapy for the treatment of E.b for some patient.This article reviews relevant literature and provides an updated and more comprehensive reference for the selection of E.b treatment drugs. To be note, the overview showed there may be individualized differences in the efficacy of Albendazole, which needs more study.
DOI: 10.6084/m9.figshare.29245334
title: Supplementary Material for: Relationships between Skin Structure and Skin Function of Pregnant Women and Their Infants: A Prospective Cohort Study

description: In women during pregnancy and in infants during the first months after birth skin health is challenged. However, evidence about the structural and functional changes of the skin during and after pregnancy is largely lacking. The first prospective cohort study was conducted, following women from pregnancy through the postpartum period and their infants until six months of age, with skin structure and function measured at different time points. Due to the explorative character of the study, descriptive statistics were used.
Over the study period, transepidermal water loss, epidermal thickness and skin roughness in women increased. Pregnancy, and postpartum period affected skin parameters such as skin roughness, epidermal thickness and transepidermal water loss, whereas stratum corneum hydration, pH, skin stiffness, and skin elasticity were not affected in women. Infants' skin barrier function matched literature values for healthy skin, with roughness and dryness decreasing through six months of age. Infant’s skin barrier function characteristics matched literature values for healthy skin, with skin roughness and dryness decreasing by six months of age.
Based on the findings of this observational cohort study we found no statistically significant correlation between maternal health and skin characteristics and skin characteristics of infants except for women’s skin roughness and infants skin stiffness and skin elasticity and women’s skin stiffness and skin elasticity and infant’s skin elasticity.
Therefore, based on our findings it may be justified to consider using skin care for maintaining barrier quality and function
a) in pregnant women with a positive effect on skin roughness and transepidermal water loss
b) in infants improving dry skin and skin roughness.
DOI: 10.6084/m9.figshare.29245334.v1
title: Supplementary Material for: Relationships between Skin Structure and Skin Function of Pregnant Women and Their Infants: A Prospective Cohort Study

description: In women during pregnancy and in infants during the first months after birth skin health is challenged. However, evidence about the structural and functional changes of the skin during and after pregnancy is largely lacking. The first prospective cohort study was conducted, following women from pregnancy through the postpartum period and their infants until six months of age, with skin structure and function measured at different time points. Due to the explorative character of the study, descriptive statistics were used.
Over the study period, transepidermal water loss, epidermal thickness and skin roughness in women increased. Pregnancy, and postpartum period affected skin parameters such as skin roughness, epidermal thickness and transepidermal water loss, whereas stratum corneum hydration, pH, skin stiffness, and skin elasticity were not affected in women. Infants' skin barrier function matched literature values for healthy skin, with roughness and dryness decreasing through six months of age. Infant’s skin barrier function characteristics matched literature values for healthy skin, with skin roughness and dryness decreasing by six months of age.
Based on the findings of this observational cohort study we found no statistically significant correlation between maternal health and skin characteristics and skin characteristics of infants except for women’s skin roughness and infants skin stiffness and skin elasticity and women’s skin stiffness and skin elasticity and infant’s skin elasticity.
Therefore, based on our findings it may be justified to consider using skin care for maintaining barrier quality and function
a) in pregnant women with a positive effect on skin roughness and transepidermal water loss
b) in infants improving dry skin and skin roughness.
DOI: 10.6084/m9.figshare.29244440
title: Toward Sustainable Web Practices in Higher Education

description: Green SEO and Digital Carbon Footprint: A Benchmark Audit of University Websites in Poland
DOI: 10.6084/m9.figshare.29244440.v1
title: Toward Sustainable Web Practices in Higher Education

description: Green SEO and Digital Carbon Footprint: A Benchmark Audit of University Websites in Poland
DOI: 10.57745/2zdnp9
title: LICENSE

description: :unav
DOI: 10.57745/6mxvrm
title: T1210_combined_scores.tab

description: :unav
DOI: 10.57745/b0ojtw
title: T1210_combined_scores.tab

description: :unav
DOI: 10.57745/faauqw
title: MassiveFold_CASP16_Abstract.pdf

description: :unav
DOI: 10.57745/j7zcvw
title: T1210_only_pdbs_MassiveFold.tar.gz

description: :unav
DOI: 10.57745/ougbjl
title: gather_runs.py

description: :unav
DOI: 10.57745/srdkdx
title: T1210_MassiveFold.tar.gz
DOI: 10.57745/vquerg
title: README.txt

description: :unav
DOI: 10.15468/dl.zhjrqd
title: Occurrence Download

description: A dataset containing 6249 species occurrences available in GBIF matching the query:
{
 "and" : [
 "OccurrenceStatus is Present",
 "TaxonKey is Antigone vipio (Pallas, 1811)"
 ]
}

 The dataset includes 6249 records from 15 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0021595-250525065834625/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.5281/zenodo.15598334
title: Plot data for "Learning-at-Criticality in Large Language Models for Quantum Field Theory and Beyond"

description: Plot data for arXiv:2506.03703. 

FIG. 1. : plot_data_s789.csv, plot_data_general.csv, result_train_matsum_o2.json

FIG. 2. : training_logs_test5.json

FIG. 3. : export_step_data_test5.json
DOI: 10.5281/zenodo.15598335
title: Plot data for "Learning-at-Criticality in Large Language Models for Quantum Field Theory and Beyond"

description: Plot data for arXiv:2506.03703. 

FIG. 1. : plot_data_s789.csv, plot_data_general.csv, result_train_matsum_o2.json

FIG. 2. : training_logs_test5.json

FIG. 3. : export_step_data_test5.json
DOI: 10.57745/a3kpc3
title: T1226_combined_scores.tab

description: :unav
DOI: 10.57745/alcc9y
title: MassiveFold_CASP16_Abstract.pdf

description: :unav
DOI: 10.57745/foopa8
title: T1226_combined_scores.tab

description: :unav
DOI: 10.57745/gorwms
title: gather_runs.py

description: :unav
DOI: 10.57745/lsir7q
title: T1226_only_pdbs_MassiveFold.tar.gz

description: :unav
DOI: 10.57745/ucgby2
title: T1226_MassiveFold.tar.gz

description: :unav
DOI: 10.57745/wi3pfj
title: LICENSE

description: :unav
DOI: 10.57745/xe9twv
title: README.txt

description: :unav
DOI: 10.25934/pr00010471
title: Validation of Predictive Molecular Biomarker for Predicting Response to Cyclin-Dependent Kinase 4 and 6 (CDK4/6) Inhibitors in Breast Cancer Using Data from PALOMA-2 and PALOMA-3 Studies

description: Breast cancer is a major health issue affecting millions of people worldwide. One type of breast cancer, called hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-), can be particularly difficult to treat, especially when it spreads to other parts of the body, which is known as metastatic breast cancer (mBC).

In HR+ breast cancer, the cancer cells have certain proteins, called hormone receptors, that can attach to hormones like estrogen and progesterone. These hormones can help the cancer cells grow. If the cancer cells have these receptors, it means the cancer is "hormone receptor-positive" (HR+), which occurs in about two-thirds of breast cancers. This type of cancer can often be treated with medicines that block the hormones, slowing the cancer’s growth.

HER2 is a protein located on the surface of breast cells that helps regulate cell growth – too much HER2 can cause cells to grow uncontrollably. HER2-negative (HER2-) means the cancer cells do not have an excess of the HER2 protein, which means that specific HER2-targeted treatments will not work for them. Understanding whether a breast cancer is HR+ and HER2- is important because it helps doctors choose the best treatment.

HR+ and HER2- breast cancer can be especially challenging to treat when it spreads, and current treatments may not work for everyone. In this form of breast cancer, treatments that target hormone receptors are often used. A newer class of drugs called cyclin-dependent kinase 4/6 inhibitors (CDK4/6 inhibitors) has shown promise in treating this type of cancer by slowing down the growth of cancer cells. However, not all patients respond equally well to these drugs, which highlights the need for better ways to predict which patients will benefit most from them. 

Our research aims to address this critical need by identifying and validating biomarkers—molecules in the blood or tissues that can indicate how well a treatment will work. Specifically, we are focusing on biomarkers that can predict how well patients with HR+/HER2- metastatic breast cancer will respond to CDK4/6 inhibitors, like palbociclib. If successful, this could lead to more personalized treatment plans, improving outcomes and reducing unnecessary side effects for patients. 
To achieve this, we will use a method called single-cell RNA sequencing. This technique allows us to examine the gene activity of individual cancer cells, helping us identify specific biomarkers associated with responses to CDK4/6 inhibitors. To confirm these findings, we will use data from two large clinical trials known as PALOMA-2 and PALOMA-3. These trials involved patients with HR+/HER2- breast cancer who were treated with palbociclib as either their first or second treatment option. By analyzing the data from these trials, we aim to validate whether our identified biomarkers can accurately predict patient responses to treatment.
DOI: 10.57745/9vnigw
title: MassiveFold_CASP16_Abstract.pdf

description: :unav
DOI: 10.57745/bzmsxy
title: gather_runs.py

description: :unav
DOI: 10.57745/kei70k
title: T1231_only_pdbs_MassiveFold.tar.gz

description: :unav
DOI: 10.57745/u4dtiy
title: T1231_combined_scores.tab

description: :unav
DOI: 10.57745/w1s06d
title: README.txt

description: :unav
DOI: 10.57745/wbcg2d
title: LICENSE

description: :unav
DOI: 10.57745/wqwpav
title: T1231_combined_scores.tab

description: :unav
DOI: 10.5281/zenodo.15598396
title: Product visuals vs. narratives
DOI: 10.5281/zenodo.15598397
title: Product visuals vs. narratives
DOI: 10.57745/rj4yop
title: T1231_MassiveFold.tar.gz

description: :unav
DOI: 10.5281/zenodo.15598488
title: Submitted Galaxy Scores to the Gravitational Wave Treasure Map for event MS250605g Initial

description: Attached in a .json file is the ranked galaxy information within the contour region of the EM counterpart search associated with the gravitational wave event MS250605g Initial. A reference to these calculations can be found here: https://ui.adsabs.harvard.edu/abs/2017ApJ...848L..33A/abstract
DOI: 10.5281/zenodo.15598489
title: Submitted Galaxy Scores to the Gravitational Wave Treasure Map for event MS250605g Initial

description: Attached in a .json file is the ranked galaxy information within the contour region of the EM counterpart search associated with the gravitational wave event MS250605g Initial. A reference to these calculations can be found here: https://ui.adsabs.harvard.edu/abs/2017ApJ...848L..33A/abstract
DOI: 10.23664/rd05-15.acdis.hiv.2018
title: AHRI HDSS.RD05-15 ACDIS HIV 2018
DOI: 10.57745/54rluw
title: gather_runs.py

description: :unav
DOI: 10.57745/etbrre
title: LICENSE

description: :unav
DOI: 10.57745/llfch8
title: MassiveFold_CASP16_Abstract.pdf

description: :unav
DOI: 10.57745/ovfjos
title: T1243_combined_scores.tab

description: :unav
DOI: 10.57745/srp7yl
title: T1243_only_pdbs_MassiveFold.tar.gz

description: :unav
DOI: 10.57745/wxgv6w
title: T1243_combined_scores.tab

description: :unav
DOI: 10.57745/x6ma48
title: T1243_MassiveFold.tar.gz

description: :unav
DOI: 10.57745/xywwyy
title: README.txt

description: :unav
DOI: 10.6084/m9.figshare.28587803
title: ERW_rawdata.csv

description: We investigated how wollastonite addition (control: 0 kg m<sup>-2</sup>, low: 0.25 kg m<sup>-2</sup>, high: 0.5 kg m<sup>-2</sup>) affect key microbial C and N-cycling genes and greenhouse gas emissions in a tropical rubber plantation.
DOI: 10.6084/m9.figshare.28587803.v2
title: ERW_rawdata.csv

description: We investigated how wollastonite addition (control: 0 kg m<sup>-2</sup>, low: 0.25 kg m<sup>-2</sup>, high: 0.5 kg m<sup>-2</sup>) affect key microbial C and N-cycling genes and greenhouse gas emissions in a tropical rubber plantation.
DOI: 10.6084/m9.figshare.28587803.v1
title: ERW_rawdata.csv

description: We investigated how wollastonite addition (control: 0 kg m<sup>-2</sup>, low: 0.25 kg m<sup>-2</sup>, high: 0.5 kg m<sup>-2</sup>) affect key microbial C and N-cycling genes and greenhouse gas emissions in a tropical rubber plantation.